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Exercise tolerance is an important outcome measure in patients with COPD, mostly because
there is evidence that exercise testing is superior to other functional measurements obtained
at rest in demonstrating the positive effect of a specific intervention. We assessed the effect
of a 5-day treatment with formoterol 12 mg twice daily on lung function, exercise capacity
and dyspnea in 22 stable COPD patients, and compared 6-MWT with 12-MWT in evaluating
formoterol efficacy. All subjects entered a crossover design. They underwent 6-MWT or 12-
MWT in a randomised order and soon after started the 5-day treatment. After a 3-day washout,
patients who had first performed 6-MWT, underwent 12-MWT, and the contrary. Formoterol
induced a progressively significant increase in pre-drug FEV1 and IC and also significant
changes in these parameters 2 h after its inhalation at each test day. Moreover, it increased
the walked distance by 53.6 m at the end of 6-MWT and 59.9 m at the end of 12-MWT. For-
moterol also induced a significant change in Borg score for dyspnea caused by the 6-MWT
when compared with the pre-treatment values, whereas it significantly changed dyspnea in-
duced by 12-MWT only after the first dose. Our study not only strengthens the importance of
walking tests as a useful tool for evaluating the impact of a bronchodilator on some COPD
patient-centred outcomes, but also indicates that 6-MWT seems to be a more appropriate in-
strument than 12-MWT for assessing the exercise response to a bronchodilator in COPD.
ª 2008 Published by Elsevier Ltd.ento di Medicina Interna,
Montpellier 1, 00133 Rome,
6 7259 6621.
iroma2.it (M. Cazzola).
8 Published by Elsevier Ltd.Introduction
Exercise tolerance has become an important outcome
measure in patients with COPD, mostly because evi-
dence has been provided that exercise testing is
Table 1 Patients’ demographics and disease severity
(GOLD) classification
Sex Age
(yrs)
FEV1
(% predicted)
FEV1/
FVC
PaO2 PaCO2 GOLD
severity
classification
M 72 40 62 70.1 41.5 III
M 56 29 51 68.7 45 IV
F 77 45 51 68.2 35.6 III
M 51 45 68 80.2 38.7 III
M 70 49 65 73.6 44.9 III
M 71 19 36 68 47.5 IV
M 81 25 42 71 51.5 IV
F 68 28 50 67 45 IV
F 62 28 69 69.4 49.2 IV
F 65 36 41 68.1 48.8 III
M 73 49 60 65.8 38.5 III
F 72 48 69 68.9 34.4 III
F 77 53 69 74.7 42.8 II
M 61 14 25 63.3 46 IV
F 74 55 40 51.3 34.5 II
M 72 49 43 60.3 40.1 III
M 75 56 60 84.6 44.4 II
M 67 48 52 85.5 40 III
M 58 55 60 70.5 41.1 II
M 65 45 55 64.5 38.9 III
F 71 38 43 59.0 42.3 III
M 62 42 49 62.8 40.7 III
1426 M. Cazzola et al.superior to other functional measurements obtained at
rest (e.g., forced expiratory volume in 1 s [FEV1]) in
demonstrating the positive effect of a specific interven-
tion.1 Pepin et al.2 recently showed that walking is
a more sensitive exercise modality to evaluate the
response to bronchodilators than cycling in patients
with COPD. This may be especially true for patients
with advanced disease in whom skeletal muscle dysfunc-
tion is more prevalent.
Part of the rationale for using the walking tests rather
than the bicycle or treadmill exercise in clinical trials is
that it is a more natural form of exercise and may better
reflect daily activity. Walking is one of the simplest and
most common activities, and consequently it is an in-
tegrative useful test to assess the physical, psychological,
and emotional capabilities of patients. It is not a surprise,
therefore, that field tests are widely used in trials
exploring the benefits of rehabilitation, pharmaceutical
intervention, oxygen supplementation and surgery in
cardiorespiratory disease.3 In particular, timed walking
tests have been shown to predict survival4 and utilization
of health-care resources5 in COPD patients. The 6-min
walking test (6-MWT) and 12-min walking tests (12-MWT)
are the most frequently used field tests to assess exercise
capacity.
The 6-MWT, which has been shown to be a submaximal
high-intensity constant-load test,1 has been widely used in
many large trials exploring the benefits of pharmaceutical
intervention,6 but only modest changes in 6-MWT of little
clinical significance have been reported following acute
bronchodilation in COPD.7 Moreover, recent research has
been suggested that the 6-MWT test may not be as respon-
sive to bronchodilation as the endurance shuttle walk.8
The 6-MWT is a self-paced test (e.g., patients determine
their own walking speed) of a fixed duration. In contrast,
the endurance shuttle walk is an externally paced test
(e.g., walking speed is dictated to patients) of an indefi-
nite duration. Improvements in performance are, there-
fore, achieved differently for the two tests.8 Patients
have to increase walking speed to cover more distance
on the 6-MWT, while they have to increase endurance
time to achieve the same outcome on the endurance shut-
tle walk.8
It has been highlighted that patients usually start
walking at a faster pace before settling to a remarkably
constant speed.9 Shortening the walking time thus tends to
measure the initial spurt rather than the true exercise
tolerance. Moreover, it has been suggested that a longer
test (12-MWT) is the best walking test for assessing the
functional capabilities of a patient.10 The basis for this con-
clusion is the observation that changes in Vo2max correlate
more closely with changes in the 12-MWT than with changes
in other walking tests.10
Nonetheless, to our best knowledge no study has directly
compared the changes induced by a treatment with
a bronchodilator in exercise performance detected by the
6-MWT with those detected by the 12-MWT.
Therefore, the present study was undertaken in
patients with stable COPD to directly compare the
changes in exercise performance detected by the 6-
MWT test with those detected by the 12-MWT test in
these patients.Methods
Subjects
Twenty-two clinically stable COPD patients capable of
performing a walking test were included in the study.
Patients with overt comorbidity preventing them from
safely performing an exercise test could not participate in
this trial. In particular, patients did not suffer from
cardiovascular, neurological disorders or advanced osteo-
arthrosis. As part of the characterisation procedures,
resting pulmonary function testing and a practice-walking
test were carried out in all patients. Patients who required
O2 during the walking test were excluded from the study.
All patients were ex-smokers and all had experience of
walking tests being included in a long-term respiratory re-
habilitation programme, but none practiced a practice-
test immediately before being enrolled in the study.
The selected patients gave their consent to participate
in the study. All trial procedures were conducted according
to the Declaration of Helsinki at the San Raffaele Hospital,
Velletri, and IRCSS San Raffaele Hospital, Rome, Italy.
Table 1 illustrates patients’ demographics and disease
severity (GOLD) classification.
Study design
After baseline assessment of pulmonary function, and
walking capacity (before exercise testing, subjects were
familiarized with the Borg scale11 and its endpoints were
Walking test for assessing the efficacy of formoterol 1427anchored such that zero represented ‘‘no breathlessness’’
and 10 was ‘‘the most severe breathlessness that they had
ever experienced or could imagine experiencing’’), and 1
week of bronchodilator washout during which the patients
could use salbutamol 200 mg as needed as ‘‘rescue’’ medica-
tion, all subjects entered a crossover design where they
underwent the 6-MWT or the 12-MWT in a randomised order
and soon after started a 5-day treatment with formoterol
12 mg bid. FEV1, inspiratory capacity (IC), walked distance
(m), and changes in Borg score from rest to the end of the
walking test were the variables measured on day 1, before
and 2 h after the first inhalation of formoterol, and on day
6 before and 2 h after the last inhalation of formoterol.
After a further 3-day washout during which, again, the
patients could use salbutamol 200 mg as needed as ‘‘rescue’’
drug, patients who had first performed 6-MWT, underwent
12-MWT, and the contrary. In this second phase, we followed
the same protocol used in the first phase.
Walking test protocol
Each clinical site used the same walking course for all
participants. The timed walking tests were conducted in an
enclosed corridor on a flat course 30 m in length according
to the procedures recommended by the American Thoracic
Society (ATS).12 To avoid interference with the patients’
exercise performance, patients walked unaccompanied
and no encouragement was given.13 Oxygen saturation
(SpO2) and heart rate (HR) were recorded continuously by
pulse oximetry. At the end of the walking tests, the partic-
ipant was told to stop, and total distance covered was cal-
culated to the nearest metre.
Pulmonary function testing
Spirometric data were obtained according to recommended
techniques.14 The patients were investigated in a sitting
position. ICwas determined by a slowmanoeuvre (slow inspi-
ration until maximum volume after regular tidal breathing).
Statistical analysis
The results of the study are expressed as mean and 95% CI
unless otherwise stated. The extent to which the two timed
field tests were able to capture changes in the measured
variables after bronchodilation was examined by the ability
of the two exercise modalities to detect statistically
significant changes using a paired t test. The end-exercise
values for the measured variables obtained during 6-MWT
and 12-MWT were compared using paired t tests and Bland
and Altman analyses.15 A p< 0.05 level of significance was
used for all analyses.
Results
In general, formoterol induced a progressively significant
increase in pre-drug FEV1 and IC and also significant
changes in these parameters 2 h after its inhalation at
each test day (Table 2).
After the first formoterol dose, both 6-MWT and 12-MWT
improved walked distance (35.3 m, 95% CI: 7.7e62.9,pZ 0.0145, and 45.8 m, 95% CI: 24.1e67.4, pZ 0.0003,
respectively) (Fig. 1). This improvement was observed
also after the 5-day treatment, before the inhalation of
the last dose that induced a further increase to 53.6 m
(95% CI: 17.6e89.3, pZ 0.0055) and 59.9 m (95% CI:
11.2e108.5, pZ 0.0182) in 6-MWT and 12-MWT, respec-
tively, when compared with the pre-treatment values.
However, we were unable to record a further significant
increase after the inhalation of the last dose in 12-MWT
when compared with the pre-inhalation values (Fig. 1). It
is intriguing that the difference in the walked distance
between 6-MWT and 12-MWT, which was 303.5 m (95% CI:
263.6e343.5) before and 314.0 m (95% CI: 272.6e355.4)
after the first inhalation of formoterol, decreased from
338.6 m (95% CI: 267.0e410.2) before to 309.8 m (95% CI:
247.7e371.9) after the inhalation of the last dose of the
same bronchodilator.
There was a statistically significant difference in the
rate of change in Borg score for dyspnea after the first dose
of formoterol (1.5, 95% CI: 2.4 to 0.5, pZ 0.0043) and
at the end of the 5-day treatment (2.3, 95% CI: 3.6e1.1,
pZ 0.0010) when compared with the pre-treatment values
only with the 6-MWT, although the last dose did not
induced a further significant decrease when compared
with the pre-inhalation of the last dose values (Fig. 2). For-
moterol significantly changed dyspnea induced by the
12-MWT only after the first dose (0.6, 95% CI: 1.1e0.1,
pZ 0.0241) (Fig. 2). The end-exercise values for the Borg
score obtained during 6-MWT and 12-MWT were signifi-
cantly different at the end of the 5-day treatment both
before (1.7, 95% CI: 2.9e0.6, pZ 0.0045) and after
(1.8, 95% CI: 2.8 to 0.8, pZ 0.0011) the inhalation
of the last dose.
Table 3 shows changes in HR and SpO2 induced by formo-
terol and walking tests. Formoterol influenced neither pre-
test HR and SpO2 nor exercise-induced HR and SpO2
changes.
There was no evidence that a specific order of testing
influenced our data.Discussion
Our study has documented that a 5-day treatment with
formoterol 12 mg twice daily increased the walked distance
by 53.6 m at the end of the 6-MWT and 59.9 m at the end of
the 12-MWT. This is, in our opinion, an important finding
because, at least for the 6-MWT, none of the studies that
have explored the effects of bronchodilators in COPD
reached the minimal clinical significance limits and, conse-
quently, the relevance of the observed effect to the patient
remains debatable.8 It must be pointed out that Redelmeier
et al.16 suggested that subjects have to improve their walk-
ing distance by 54 m after a 6-MWT in order to appreciate
this increase as a beneficial effect, whereas Troosters
et al.17 reported a mean increase of 52 m in a study of
the short- and longer-term benefits of pulmonary rehabili-
tation delivered over a 6-month period. As far as we are
aware, the minimal clinical significance levels in the other
tests of exercise capacity have not been defined. There-
fore, also for the 12-MWT, the minimal clinically relevant
distance is unknown.
Table 2 Changes in FEV1 and IC induced by formoterol 12 mg twice daily
6-MWT 12-MWT
FEV1 (L) IC (L) FEV1 (L) IC (L)
1st day before first dose 1.019 (0.8372e1.201) 1.797 (1.511e2.082) 1.027 (0.826e1.229) 1.676 (1.437e1.916)
1st day 2 h after first dose 1.186 (0.953e1.419) 2.182 (1.956e2.408) 1.200 (1.004e1.396) 2.005 (1.728e2.281)
6th day before last dose 1.135 (0.949e1.322) 1.945 (1.695e2.194) 1.139 (0.936e1.342) 2.063 (1.775e2.351)
6th day after last dose 1.185 (0.979e1.391) 2.045 (1.737e2.353) 1.231 (1.016e1.446) 2.205 (1.952e2.457)
Values are mean and 95% CI.
1428 M. Cazzola et al.It is interesting that our data show that a 5-day
treatment with formoterol 12 mg twice daily has allowed
not only to reach the minimal clinical significance limit pro-
posed by Troosters et al.,17 but also to obtain a significant
change in Borg score for dyspnea induced by the 6-MWT
when compared with the pre-treatment values.
We believe that these results support the use of the
6-MWT as a relatively simple test to be used extensively in
trials to evaluate possible benefits of pharmacological
intervention as suggested by the ATS/ERS Task Force on
outcomes for COPD pharmacological trials.18 Obviously, this
opinion contrasts with the documentation that the 6-MWT is
not really responsive for detecting changes in exercise
performance following bronchodilation.6 It is well known
that the 6-MWT is not physiologically pure because it is
self-paced and, unless appropriately conducted, may be
subject to learning and motivation effects.19 Furthermore,
it is a physiological hybrid test that may produce erratic
metabolic demand that may include peak or endurance per-
formance.19 Nonetheless, the 6-MWT is probably the most
popular investigation because of its simplicity, relevance
to daily life, widespread use and availability of reference
values.19
We must highlight that in this study we have used
formoterol as test bronchodilator because there is evidence
that inhaled formoterol 12 mg twice daily is effective in
ameliorating exercise intolerance even in patients with ad-
vanced COPD.20 In effect, it is able to reduce the level of1D before 1D after 6D before 6D after
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Figure 1 Changes in distance walked with formoterol for the
6 min walking test (6-MWT) and the 12 min walking test
(12-MWT). Values are mean SE. *p< 0.05, **p< 0.01,
***p< 0.001 vs. pre-treatment; #p< 0.05 vs. pre-last dose. 1D
before, first day before inhalation of formoterol; 1D after, first
day after inhalation of formoterol; 6D before, sixth day before
inhalation of formoterol; 6D after, sixth day after inhalation of
formoterol.resting and exercise-related dynamic hyperinflation with
consequential benefits on effort tolerance and breathless-
ness on daily living in severely disabled patients with ad-
vanced COPD.20 The degree of dynamic hyperinflation can
be assessed by measuring reduction in IC.21 It has been sug-
gested that changes in IC, which might imply improvements
in dynamic hyperinflation, can reduce exercise-induced
dyspnea.22 In our patients, formoterol induced a significant
improvement in IC. However, this improvement elicited
changes in dyspnea and walked distance only after the
6-MWT. In fact, formoterol significantly changed dyspnea
induced by the 12-MWT only after the first dose whereas
there was a significant difference between the 6-MWT and
12-MWT in favour of the 6-MWT at the end of the 5-day
treatment with formoterol. Moreover, the difference in
the walked distance between 6-MWT and 12-MWT
decreased after the inhalation of the last dose of this
bronchodilator.
It is intriguing that three double-blind studies using
another long-acting b2-agonist salmeterol, 50e100 mg bid,
did not find a significant effect on walking distance (after
4, 16, and 12 weeks, respectively), despite a significant
improvement in FEV1 in the first two studies
8 and the
fact that salmeterol is able to reduce lung hyperinflation
at rest and during exercise with associated improvements
in exercise endurance time.23 It must be highlighted that
O’Donnell et al.24 studied the effect of ipratropium
bromide on exercise tolerance in patients with COPD.1D before 1D after 6D before 6D after
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6-MWT
12-MWT
*
**
***
**
 
B
o
r
g
 
s
c
o
r
e
Figure 2 Changes in the exercise-induced dyspnea (Borg
score) with formoterol for the 6 min walking test (6-MWT)
and the 12 min walking test (12-MWT). Values are mean SE.
*p< 0.05; **p< 0.01; ***p< 0.001 vs. pre-treatment. 1D
before, first day before inhalation of formoterol; 1D after, first
day after inhalation of formoterol; 6D before, sixth day before
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Walking test for assessing the efficacy of formoterol 1429Although bronchodilation had a positive effect on exercise
tolerance on the group as a whole, the improvement in
endurance during submaximal exercise was only moder-
ately correlated with the change in FEV1 and IC induced
by bronchodilation. In fact, ipratropium bromide in ap-
proximately 20% of patients, failed to improve endurance
time despite positive effects on lung function. These
interesting findings suggest that factors other than impair-
ment in lung function must be involved in exercise limita-
tion in COPD. The duration of exercise likely contributes
to muscle fatigue and it is well known that peripheral
muscle fatigue is a potential contributor to exercise intol-
erance in COPD.2 Peripheral muscle fatigue, which we
have not evaluated in this study, might explain why formo-
terol was unable to improve dyspnea and walked distance
after the 12-MWT.
In any case, our findings do not allow to exclude that
the supposed impact of a learning experience when
repetitive tests are performed25 has influenced the results
that we have obtained when we have evaluated the im-
pact of formoterol on 6-MWT, but they also indicate that
this learning experience is not important when the impact
of the same bronchodilator is evaluated by the changes in
12-MWT.
We have considered only a 5-day treatment because
our aim was not that of confirm the usefulness of a regular
treatment with formoterol in improving exercise capacity
in COPD patients, but that of directly comparing the
changes in exercise performance detected by the 6-MWT
test with those detected by the 12-MWT test these
patients. For doing it, we preferred to use a fast but
also long-acting agent but we also considered that other
known muscle effects of ß2-agonists are those on skeletal
muscle force. ß2-Agonists ‘muscle type’ increase the con-
traction force of the fast-contracting muscle type, which
can influence the walking tests. Unfortunately, there is
documentation that a marked tolerance develops for ß2-
agonist-induced increases in force generation of the
fast-contracting muscle type by transmural stimulation
ex vivo.26 It can be envisaged that such downregulation
or uncoupling of skeletal muscle ß2-receptors also occurs
after maintenance formoterol treatment and may lead
to fewer functional ß2-receptors being available to endog-
enous catecholamines released during exercise.
In conclusion, our study strengths the importance of
walking tests as a useful tool for evaluating the impact of
a bronchodilator on some COPD patient-centred outcomes,
but also indicates that 6-MWT seems to be a more appro-
priate instrument than 12-MWT for assessing the exercise
response to a bronchodilator in COPD. This is an intriguing
information that deserves further investigation considering
that recently it has been documented that in patients with
severe airflow limitation (FEV1< 50% predicted), 6-MWT de-
clines over time, whereas the rate of FEV1 loss over time is
lower at the more severe stages of the disease.27Conflict of interest statement
All Authors have no conflicts to disclose for this paper that
describes a spontaneous study, which was not supported by
any Drug Company.
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